Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATI-9242 is a novel, atypical antipsychotic small molecule developed for the treatment of schizophrenia. It is a dibenzo(b,f)(1,4)oxazepine derivative designed to provide efficacy similar to clozapine but with fewer adverse effects. The drug acts on multiple neurotransmitter systems, including serotonin (5-HT1A agonist, 5-HT2A antagonist, 5-HT7 modulator), dopamine (D2 antagonist), acetylcholine (stimulant), GABA (modulator), and NMDA receptors (modulator). Its broad mechanism aims to address both positive and negative symptoms of schizophrenia while minimizing side effects commonly associated with other antipsychotics[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ATI-9242.